Investors
#FutureFresenius is clearly paying off:
- We’ve created a simpler, more focused and stronger healthcare company since the launch of our #FutureFresenius transformation end of 2022 – creating long-term value!
- We’ve successfully concluded several important strategic portfolio measures, completed the deconsolidation of Fresenius Medical Care (FME), exited Vamed and reduced our stake in FME
- We’ve set ambitious EBIT margin bands for our Operating Companies Fresenius Kabi and Fresenius Helios with our Fresenius Financial Framework
Kicked off REJUVENATE phase with strong momentum:
- We’ve started 2025 and the next phase of #FutureFresenius – Rejuvenate – with excellent performance across the company and confirm our full-year guidance
- Very strong 12% EPS growth driven by operating strength and significant lower interest expense
- Fresenius Kabi delivering very strong 16.8% EBIT margin; Biopharma moving close to structural EBIT margin range
- Fresenius Helios Performance Programme gaining traction and delivering on schedule
- Leverage within new target corridor
- Executing on value-enhancing capital allocation strategy with sale of stake in FME
Read more about our company strategy!

May 23, 2025
Frankfurt, Germany
Annual General Meeting 2025
Information, Documents and Shareholder Online Service
May 07, 2025 - 01:30 pm
Bad Homburg, Germany
Conference Call Q1 2025

“We've kick-started 2025 with an excellent performance across the business and confirm our full-year guidance. Organic revenue increased by 7% driven by the consistent delivery of Fresenius Kabi and Fresenius Helios. This along with continued improvements in operations and lower interest costs led to an impressive EPS growth of 12%. Following the reduction of our stake in Fresenius Medical Care, a first and pivotal milestone in our history, we now start the REJUVENATE phase of #FutureFresenius from an even stronger position; this step underscores our commitment to creating long-term value. With a strengthened balance sheet and capital allocation priorities to further invest in our growth platforms, while also increasing our US presence, Fresenius is well positioned to deliver future profitable growth and innovation.”
Michael Sen, Chairman of the Management Board
Financial Results
Strong Q4 2024 concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase!
Outlook
Upgraded outlook for FY 2024 achieved: A detailed overview of our outlook for the Group and Operating Companies in 2025!
Dividends
We defined a new dividend policy designed to ensure attractive shareholder returns while maintaining strategic flexibility. Read more!
Goals & Strategy
#CommittedToLife: The health and well-being of our patients is Fresenius' top priority. Find out more about our corporate strategy!
Investor Feedback
Open dialogue is valuable for us.
You can submit your feedback quickly and easily using the link below (anonymously if you prefer).
You will be redirected to QuantiFire which conducts this survey in own controllership.
